Enterprise Value

-26.27M

Cash

45.5M

Avg Qtr Burn

-10.3M

Short % of Float

0.52%

Insider Ownership

8.62%

Institutional Own.

19.57%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ONCT-534 Details
Cancer, Castration-resistant prostate cancer

Phase 1/2

Data readout

ONCT-808 (CAR-T) Details
Hematologic malignancies, Cancer, B-cell lymphoma

Phase 1/2

Data readout

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma

Failed

Discontinued

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Cancer, Mantle cell lymphoma

Failed

Discontinued

ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details
Relapsed/refractory Ewing sarcoma, Cancer

Failed

Discontinued